1. Analyst View 2. Research Methodolog 3. Parkinson’s Disease: An Overview 4. Market Dynamics 4.1 Drivers 4.1.1 Increasing Funding Support & Research Grants 4.1.2 Increasing Awareness 4.1.3 Rising Healthcare Expenditure 4.1.4 Increasing Life Expectancy 4.2 Challenges 4.2.1 Patent Expiry of Blockbuster Drugs 4.2.2 High Cost of Treatment 4.2.3 Side-Effects of Parkinson’s Disease Drugs 4.3 Opportunities 4.3.1 Collaborations with Academic Institutions for Developing Innovative Solutions 4.3.2 Reduction in “Off” Time to Improve Patient and Economic Outcomes 4.3.3 Growing Geriatric Population 5. Global Parkinson’s Disease Drugs Market Outlook 2022 6. Major Products in Parkinson’s Disease Market 6.1 Duodopa/Duopa 6.2 Azilect 6.3 Mirapex/Mirapex ER 6.4 Requip 6.5 Neupro 6.6 Rytary/Numient 6.7 Xadago 6.8 Nuplazid 7. Market Segmentation by Type of Therapy 7.1 Levodopa Therapy 7.2 Dopamine Agonist Therapy 7.3 MAO-B Inhibitor Therapy 7.4 COMT Inhibitor Therapy 7.5 Other Therapy 8. Market Segmentation by Geography 8.1 North America 8.2 Europe 8.3 Asia-Pacific 9. Trends & Developments 9.1 Stem Cell Therapies - Revolutionizing Parkinson Treatment 9.2 Incessant Launch of Novel Products 10. Mergers & Acquisitions 11. Drugs Pipeline of Parkinson’s Disease 12. Company Profiles 12.1 Abbvie Inc. 12.2 Newron Pharmaceuticals SpA 12.3 Acadia Pharmaceuticals Inc. 12.4 Boehringer Ingelheim International GmbH 12.5 Teva Pharmaceutical Industries Limited 12.6 GlaxoSmithKline plc 12.7 UCB S.A. 12.8 Novartis AG 12.9 Impax Laboratories, Inc. 12.10 Valeant Pharmaceuticals International, Inc. 12.11 Merck & Co., Inc. 12.12 Mylan N.V. 12.13 F. Hoffmann-La Roche Ltd. 12.14 US WorldMeds, LLC

List of Tables: Table 10-1: Mergers, Acquisitions & Collaborations in Parkinson’s Disease Drugs Market (2015-2017) Table 11-1: Global - Drugs Pipeline of Parkinson’s Disease Table 12-1: Abbvie Inc. - Key Financials (Billion US$), 2014-2016 Table 12-2: Abbvie Inc. - Marketed Parkinson’s Disease Products Table 12-3: Abbvie Inc. - Parkinson’s Disease Products in Pipeline Table 12-4: Newron Pharmaceuticals SpA - Key Financials (Million US$), 2014-2016 Table 12-5: Newron Pharmaceuticals SpA - Marketed Parkinson’s Disease Products Table 12-6: Newron Pharmaceuticals SpA - Parkinson’s Disease Products in Pipeline Table 12-7: Acadia Pharmaceuticals Inc. - Key Financials (Million US$), 2014-2016 Table 12-8: Acadia Pharmaceuticals Inc. - Marketed Parkinson’s Disease Products Table 12-9: Boehringer Ingelheim International GmbH - Key Financials (Billion US$), 2014-2016 Table 12-10: Boehringer Ingelheim International GmbH - Marketed Parkinson’s Disease Products Table 12-11: Teva Pharmaceutical Industries Limited - Key Financials (Billion US$), 2014-2016 Table 12-12: Teva Pharmaceutical Industries Limited - Marketed Parkinson’s Disease Products Table 12-13: GlaxoSmithKline plc - Key Financials (Billion US$), 2014-2016 Table 12-14: GlaxoSmithKline plc - Marketed Parkinson’s Disease Products Table 12-15: UCB S.A. - Key Financials (Billion US$), 2014-2016 Table 12-16: UCB S.A. - Marketed Parkinson’s Disease Products Table 12-17: UCB S.A. - Parkinson’s Disease Products in Pipeline Table 12-18: Novartis AG - Key Financials (Billion US$), 2014-2016 Table 12-19: Novartis AG - Marketed Parkinson’s Disease Products Table 12-20: Impax Laboratories, Inc. - Key Financials (Million US$), 2014-2016 Table 12-21: Impax Laboratories, Inc. - Marketed Parkinson’s Disease Products Table 12-22: Impax Laboratories, Inc. - Parkinson’s Disease Products in Pipeline Table 12-23: Valeant Pharmaceuticals International, Inc. - Key Financials (Billion US$), 2014-2016 Table 12-24: Valeant Pharmaceuticals International, Inc. - Marketed Parkinson’s Disease Products Table 12-25: Merck & Co., Inc. - Key Financials (Million US$), 2014-2016 Table 12-26: Merck & Co., Inc. - Marketed Parkinson’s Disease Products Table 12-27: Mylan N.V. - Key Financials (Billion US$), 2014-2016 Table 12-28: Mylan N.V. - Marketed Parkinson’s Disease Products Table 12-29: F. Hoffmann-La Roche Ltd. - Key Financials (Billion US$), 2014-2016 Table 12-30: F. Hoffmann-La Roche Ltd. - Marketed Parkinson’s Disease Products Table 12-31: F. Hoffmann-La Roche Ltd. - Parkinson’s Disease Products in Pipeline Table 12-32: US WorldMeds, LLC - Marketed Parkinson’s Disease Products Table 12-33: US WorldMeds, LLC - Parkinson’s Disease Products in Pipeline List of Figures: Figure 4-1: Global - Population 60 Years or Above (Billion), 2015, 2030 & 2050 Figure 5-1: Global - Parkinson’s Disease Drugs Market (Billion US$), 2016 & 2022 Figure 6-1: Global - Sales of Duodopa/Duopa (Billion US$), 2015 & 2016 Figure 6-2: Global - Sales of Azilect (Billion US$), 2015 & 2016 Figure 6-3: Global - Sales of Mirapex/Mirapex ER (Billion US$), 2015 & 2016 Figure 6-4: Global - Sales of Requip (Billion US$), 2015 & 2016 Figure 6-5: Global - Sales of Neupro (Billion US$), 2015 & 2016 Figure 6-6: Global - Sales of Rytary/Numient (Billion US$), 2015 & 2016 Figure 7-1: Global - Parkinson’s Disease Drugs Market by Type of Therapy (%), 2016 Figure 7-2: Global - Levodopa Therapy Market for Parkinson’s Disease (Billion US$), 2016 & 2022 Figure 7-3: Global - Dopamine Agonist Therapy Market for Parkinson’s Disease (Billion US$), 2016 & 2022 Figure 7-4: Global - MAO-B Inhibitor Therapy Market for Parkinson’s Disease (Billion US$), 2016 & 2022 Figure 7-5: Global - COMT Inhibitor Therapy Market for Parkinson’s Disease (Billion US$), 2016 & 2022 Figure 7-6: Global - Other Therapy Market for Parkinson’s Disease (Billion US$), 2016 & 2022 Figure 8-1: Global - Parkinson’s Disease Drugs Market by Geography (%), 2016 Figure 8-2: North America - Parkinson’s Disease Drugs Market (Billion US$), 2016 & 2022 Figure 8-3: North America - Population 60 Years or Above (Million), 2015, 2030 & 2050 Figure 8-4: Europe - Parkinson’s Disease Drugs Market (Billion US$), 2016 & 2022 Figure 8-5: Asia-Pacific - Parkinson’s Disease Drugs Market (Billion US$), 2016 & 2022 Figure 12-1: Abbvie Inc. - Breakup of Revenue by Geography (%), 2016 Figure 12-2: Boehringer Ingelheim International GmbH - Breakup of Sales by Business Segment (%), 2016 Figure 12-3: Boehringer Ingelheim International GmbH - Breakup of Sales by Geography (%), 2016 Figure 12-4: Teva Pharmaceutical Industries Limited - Breakup of Revenue by Business Segment (%), 2016 Figure 12-5: Teva Pharmaceutical Industries Limited - Breakup of Revenue by Geography (%), 2016 Figure 12-6: GlaxoSmithKline plc - Breakup of Group Turnover by Business Segment (%), 2016 Figure 12-7: GlaxoSmithKline plc - Breakup of Group Turnover by Geography (%), 2016 Figure 12-8: UCB S.A. - Breakup of Revenue by Geography (%), 2016 Figure 12-9: Novartis AG - Breakup of Sales by Business Segment (%), 2016 Figure 12-10: Novartis AG - Breakup of Pharmaceuticals Division Sales by Segment (%), 2016 Figure 12-11: Novartis AG - Breakup of Sales by Geography (%), 2016 Figure 12-12: Impax Laboratories, Inc. - Breakup of Revenue by Business Segment (%), 2016 Figure 12-13: Valeant Pharmaceuticals International, Inc. - Breakup of Revenue by Business Segment (%), 2016 Figure 12-14: Valeant Pharmaceuticals International, Inc. - Breakup of Revenue by Geography (%), 2016 Figure 12-15: Merck & Co., Inc. - Sales by Business Segments (%), 2016 Figure 12-16: Merck & Co., Inc. - Sales by Geography (%), 2016 Figure 12-17: Mylan N.V. - Breakup of Revenue by Geography (%), 2016 Figure 12-18: F. Hoffmann-La Roche Ltd. - Breakup of Sales by Business Segment (%), 2016